- Who We Are
- Our Approach
- Clinical Expertise
- Our Products
Changing the trajectory of cancer mortality requires a new way of thinking about early detection, and with the convergence of technological innovation in human genomics and machine learning, this is no longer science fiction. It is today’s scientific reality.
We’ve harnessed this technology to pioneer Galleri™, a simple blood test that can detect over 50 types of cancers — over 45 of which lack recommended screening today — with a low false positive rate, through a single blood draw.
We are collaborating with leading health systems, academic medical centers, and industry partners around the world to help bring our groundbreaking technology to patients.
Our unique ability to sequence broadly across the genome allows us to detect multiple deadly cancers, even at earlier stages, through a single blood draw. This not only provides the opportunity for earlier treatment, but with a single low false positive rate, it helps reduce the potential harms associated with false alarms. Galleri is intended to be used in addition to, and not replace, recommended cancer screening tests.
Tumors shed cell-free nucleic acids (cfDNA) into the blood, carrying signals specific to cancer. When detected, these signals provide insight into where the cancer is located in the body (for example, the lung or ovary). Using our proprietary technology to detect and identify these signals, we’re able to detect cancer early, potentially before symptoms are present.
We’re conducting what we believe to be one of the largest clinical study programs in genomic medicine, and as a result, generating massive data sets -- over 12 petabytes in total. This equates to more than one million gigabytes.
To interpret these data, we have deployed cutting-edge data and computer science tools, and are leveraging powerful machine learning to both detect cancer signals, and identify the signal’s location in the body.